Prophylaxis of febrile neutropenia in adults receiving chemotherapy needs to be adapted to the risk

References

• Bodey GP. The changing face of febrile neutropenia: from monotherapy to moulds to mucositis. Fever and neutropenia: the early years. J Antimicrob Chemother 2009;63:i3-13
   PubMedGoogle Scholar
• McCabe W, Jackson G. Gram-negative bacteremia: II. Clinical, laboratory and therapeutic observations. Arch Intern Med 1962;110:856-64
   Google Scholar
• Schimpff S, Satterlee W, Young VM, et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971;284:1061-5
   PubMed Web of Science ®Google Scholar
• Klastersky J. Empiric treatment of infections in neutropenic patients with cancer. Rev Infect Dis 1983;5:S21-31
   Google Scholar
• Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta-lactam aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 2003;326:1111
   PubMed Web of Science ®Google Scholar
• Klastersky J, Debusscher L, Weerts D, et al. Use of oral antibiotics in protected units environment: clinical effectiveness and role in the emergence of antibiotic-resistant strains. Pathol Biol (Paris) 1974;22:5-12
   PubMedGoogle Scholar
• EORTC International Antimicrobial Therapy Project Group. Trimethoprim-sulfamethoxazole in the prevention of infection in neutropenic patients. J Infect Dis 1984;150:372-9
   PubMed Web of Science ®Google Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. Organisation of research and treatment of cancer. 2010 update of EORTC guidelines for the use of granulocyte colony-stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47:8-32
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Quaresmini G, Casari S, et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother 2008;61:721-8
   PubMed Web of Science ®Google Scholar
• Klastersky J, Ameye L, Maertens J, et al. Bacteremia in febrile neutropenic patients. Int J Antimicrob Agents 2007;30(Suppl 1):S51-9
   PubMed Web of Science ®Google Scholar
• Klastersky J, Gombos A, Georgala A, et al. Prevention of neutropenia-related events in elderly patients with hematological cancer. Aging Health 2011;7:829-42
   Google Scholar
• Elting L, Lu C, Escalante C, et al. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 2008;26:606-11
   PubMed Web of Science ®Google Scholar
• Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-51
   PubMed Web of Science ®Google Scholar
• Klastersky J, Paesmans M. The Multinational Association for Supportive Care in Cancer (MASCC) risk index: ten years of use identifying low-risk febrile neutropenic cancer patients. Support Care Cancer 2013;21:1487-95
   PubMed Web of Science ®Google Scholar
• Paesmans M, Klastersky J, Maertens J, et al. Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter? Support Care Cancer 2011;19:1001-8
   PubMed Web of Science ®Google Scholar
• Innes H, Lim SL, Hall A, et al. Management of febrile neutropenia in soid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer 2008;16:485-91
   PubMed Web of Science ®Google Scholar
• Kern WV, Marchetti O, Drgoina L, et al. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy – EORTC infectious diseases group trial XV. J Clin Oncol 2013;31:1149-56
   PubMed Web of Science ®Google Scholar
• Rolston KV, Frisbee-Hume SE, Patel S, et al. Oral moxifloxacin for outpatients treatment of low-risk, febrile neutropenic patients. Support Care Cancer 2010;18:89-94
   PubMed Web of Science ®Google Scholar
• Freifeld A, Bow E, Sepkowitz K, et al. Executive summary: clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer. 2010 update by infectious diseases society of America. Clin Infect Dis 2011;52:e56-93
   PubMedGoogle Scholar
• Marti F, Cullen MH, Roila F. Management of febrile neutropenia: ESMO clinical recommendations. Ann Oncol 2009;20:iv166-9
   Web of Science ®Google Scholar
• Ahn S, Lee YS, Chun YH, et al. Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia. Support Care Cancer 2011;19:1151-8
   PubMed Web of Science ®Google Scholar
• Best JT, Freith K, Anderson F, et al. Implementation of an evidence-based order set to impact initial antibiotic time intervals in adult febrile neutropenia. Oncol Nurs Forum 2011;38:661-8
   PubMed Web of Science ®Google Scholar
• Sammut SJ, Mazhar D. Management of febrile neutropenia in an acute oncology service. QJM 2012;105:327-36
   PubMed Web of Science ®Google Scholar
• Mato A, Luger S, Heitjan D, et al. Elevation in serum lactate at the time of febrile neutropenia (FN) in hemodynamically-stable patients with hematologic malignancies (HM) is associated with the development of septic shock within 48 hours. Cancer Biol Ther 2010;9:585-9
   PubMed Web of Science ®Google Scholar
• Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-70
   PubMed Web of Science ®Google Scholar
• Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178-84
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158-67
   PubMed Web of Science ®Google Scholar
• Cooper KL, Madan J, Whyte S, et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 2011;11:404
   PubMed Web of Science ®Google Scholar
• Naeim A, Henk HJ, Becker L, et al. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer 2013;3:11
   Google Scholar
• Morrison VA, Wong M, Hershman D, et al. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm 2007;13:337
   PubMed Web of Science ®Google Scholar
• Weycker D, Malin J, Kim J, et al. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther 2009;31:1069
   PubMed Web of Science ®Google Scholar
• Papaldo P, Lopez M, Marolla P, et al. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubin and cyclophosphamide. J Clin Oncol 2005;23:6908-18
   PubMed Web of Science ®Google Scholar
• Klastersky J, Awada A, Aoun M, et al. Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended? Curr Opin Oncol 2009;21:297-302
   PubMed Web of Science ®Google Scholar
• Gafter-Gvili A, Paul M, Fraser A, et al. Effects of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance. Systematic review and meta-analysis. J Antimicrob Chemother 2007;59:5-22
   PubMed Web of Science ®Google Scholar
• Klastersky J, Georgala A. Strategies for the empirical management of infection in cancer patients with emphasis on the emergence of resistant Gram-negative bacteria. Crit Rev Oncol Hematol 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar